Meta-analysis of 94,492 patients with hypertension treated with beta Blockers to determine the risk of new-onset diabetes Mellitus

被引:211
作者
Bangalore, Sripal [1 ]
Parkar, Sanobar
Grossman, Ehud
Messerli, Franz H.
机构
[1] St Lukes Roosevelt Hosp, Dept Med, New York, NY 10025 USA
[2] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA
[3] Sackler Sch Med, Tel Hashomer, Israel
[4] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
关键词
D O I
10.1016/j.amjcard.2007.05.057
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Beta blockers used for the treatment of hypertension may be associated with increased risk for new-onset diabetes mellitus (DM). A search of Medline, PubMed, and EMBASE was conducted for randomized controlled trials of patients taking 0 blockers as first-line therapy for hypertension with data on new-onset DM and follow-up for :l year. Twelve studies evaluating 94,492 patients fulfilled the inclusion criteria. Beta-blocker therapy resulted in a 22% increased risk for new-onset DM (relative risk 1.22, 95% confidence interval [CI] 1.12 to 1.33) compared with nondiuretic antihypertensive agents. A higher baseline fasting glucose level (odds ratio [OR] 1.01, 95% CI 1.00 to 1.02, p = 0.004) and greater systolic (OR 1.05, 95% CI 1.05 to 1.08, p = 0.001) and diastolic (OR 1.06, 95% CI 1.0 1 to 1. 10, p = 0.0 11) blood pressure differences between the 2 treatment modalities were significant univariate predictors of new-onset DM. Multivariate meta-regression analysis showed that a higher baseline body mass index (OR 1.17, 95% CI 1.01 to 1.33, p = 0.034) was a significant predictor of new-onset DM. The risk for DM was greater with atenolol, in the elderly, and in studies in which R blockers were less efficacious antihypertensive agents and increased exponentially with increased duration on R blockers. For the secondary end points, beta blockers resulted in a 15% increased risk for stroke, with no benefit for the end point of death or myocardial infarction. In conclusion, 13 blockers are associated with an increased risk for new-onset DM, with no benefit for the end point of death or myocardial infarction and with a 15% increased risk for stroke compared with other agents. This risk was greater in patients with higher baseline body mass indexes and higher baseline fasting glucose levels and in studies in which beta blockers were less efficacious antihypertensive agents compared with other treatments. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1254 / 1262
页数:9
相关论文
共 47 条
[1]   Diabetes and cardiovascular events in hypertensive patients [J].
Alderman, MH ;
Cohen, H ;
Madhavan, S .
HYPERTENSION, 1999, 33 (05) :1130-1134
[2]   Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial [J].
Bakris, GL ;
Fonseca, V ;
Katholi, RE ;
McGill, JB ;
Messerli, FH ;
Phillips, RA ;
Raskin, P ;
Wright, JT ;
Oakes, R ;
Lukas, MA ;
Anderson, KM ;
Bell, DSH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18) :2227-2236
[3]  
BERGLUND G, 1986, ACTA MED SCAND, V220, P419
[4]  
Bosch J, 2006, NEW ENGL J MED, V355, P1551
[5]  
Bradburn MJ, 1998, STATA TECH B REPRINT, V44, P4
[6]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[7]   Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].
Dahlöf, B ;
Sever, PS ;
Poulter, NR ;
Wedel, H ;
Beevers, DG ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2005, 366 (9489) :895-906
[8]   EPINEPHRINE-INDUCED INSULIN RESISTANCE IN MAN [J].
DEIBERT, DC ;
DEFRONZO, RA .
JOURNAL OF CLINICAL INVESTIGATION, 1980, 65 (03) :717-721
[9]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[10]   Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study [J].
Dunder, K ;
Lind, L ;
Zethelius, B ;
Berglund, L ;
Lithell, H .
BRITISH MEDICAL JOURNAL, 2003, 326 (7391) :681-684